Julie Bynum1,2,3, Honor Passow3, Donald Carmichael3, Jonathan Skinner3,4,5. 1. Department of Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan. 2. Institute of Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan. 3. Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire. 4. Department of Economics, Dartmouth College, Hanover, New Hampshire. 5. National Bureau of Economic Research, Cambridge, Massachusetts.
Abstract
OBJECTIVES: To examine prostate-specific antigen (PSA) screening practice change in subgroups of men defined in guidelines and in various regions and to identify factors associated with change in screening practices. DESIGN: Observational study using serial cross-sections, 2003 to 2013. SETTING: National fee-for-service Medicare. PARTICIPANTS: Men aged 68 and older eligible for prostate cancer screening. MEASUREMENTS: National PSA screening practices in men aged 68 and older from 2003 to 2013 and change in regional screening rates in men aged 75 and older. RESULTS: The PSA screening rate in men aged 68 and older was 17.2% in 2003, 22.3% in 2008, and 18.6% in 2013 (p < .001 for all differences); rates ended slightly lower than rates in 2003 only in men 80 and older. Racial disparities in screening became less pronounced over this period. In men aged 75 and older, change in regional screening rates varied widely, with absolute rates growing by 15 per 100 enrollees in some areas and declining by the same amount in others. Areas with high social capital, a measure associated with diffusion of new ideas, were more likely to decline; malpractice intensity and managed care penetration had no effect. CONCLUSION: Studying Medicare enrollees over time, we found little reduction in PSA screening and even increases according to race and in some regions. The heterogeneous changes across regions suggest that consistent reduction in the use of low-value care may require change strategies that go beyond evidence and guidelines to include monitoring and feedback on performance. J Am Geriatr Soc 67:29-36, 2019.
OBJECTIVES: To examine prostate-specific antigen (PSA) screening practice change in subgroups of men defined in guidelines and in various regions and to identify factors associated with change in screening practices. DESIGN: Observational study using serial cross-sections, 2003 to 2013. SETTING: National fee-for-service Medicare. PARTICIPANTS: Men aged 68 and older eligible for prostate cancer screening. MEASUREMENTS: National PSA screening practices in men aged 68 and older from 2003 to 2013 and change in regional screening rates in men aged 75 and older. RESULTS: The PSA screening rate in men aged 68 and older was 17.2% in 2003, 22.3% in 2008, and 18.6% in 2013 (p < .001 for all differences); rates ended slightly lower than rates in 2003 only in men 80 and older. Racial disparities in screening became less pronounced over this period. In men aged 75 and older, change in regional screening rates varied widely, with absolute rates growing by 15 per 100 enrollees in some areas and declining by the same amount in others. Areas with high social capital, a measure associated with diffusion of new ideas, were more likely to decline; malpractice intensity and managed care penetration had no effect. CONCLUSION: Studying Medicare enrollees over time, we found little reduction in PSA screening and even increases according to race and in some regions. The heterogeneous changes across regions suggest that consistent reduction in the use of low-value care may require change strategies that go beyond evidence and guidelines to include monitoring and feedback on performance. J Am Geriatr Soc 67:29-36, 2019.
Authors: Garth H Rauscher; Timothy P Johnson; Young Ik Cho; Jennifer A Walk Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-04-01 Impact factor: 4.254
Authors: H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman Journal: J Urol Date: 2013-05-06 Impact factor: 7.450
Authors: Tomy Y Perez; Matthew R Danzig; Rashed A Ghandour; Ketan K Badani; Mitchell C Benson; James M McKiernan Journal: Urology Date: 2014-11-11 Impact factor: 2.649
Authors: Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245
Authors: Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal Journal: N Engl J Med Date: 2016-09-14 Impact factor: 91.245
Authors: Kirsten L Greene; Peter C Albertsen; Richard J Babaian; H Ballentine Carter; Peter H Gann; Misop Han; Deborah Ann Kuban; A Oliver Sartor; Janet L Stanford; Anthony Zietman; Peter Carroll Journal: J Urol Date: 2009-09-24 Impact factor: 7.450
Authors: Joshua A Cohn; Chihsiung E Wang; Justin C Lakeman; Jonathan C Silverstein; Charles B Brendler; Kristian R Novakovic; Michael S McGuire; Brian T Helfand Journal: Urol Oncol Date: 2013-08-02 Impact factor: 3.498
Authors: Nathaniel Oswald; Tengda Lin; Benjamin Haaland; Michael Flynn; Kensaku Kawamoto; Kathleen A Cooney; William Lowrance; Heidi A Hanson; Brock O'Neil Journal: Cancer Epidemiol Date: 2020-05-08 Impact factor: 2.984
Authors: Carlos Irwin A Oronce; A Mark Fendrick; Joseph A Ladapo; Catherine Sarkisian; John N Mafi Journal: J Gen Intern Med Date: 2021-04-14 Impact factor: 5.128